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Abstract: We report a 52-year-old female with end-stage osteoarthritis of the hip accompanied by acetabular dysplasia in whom quality 
of life (QOL) was improved by Kampo treatment. 
When she was 42 years old, she developed pain in the left hip joint, and early-stage OA of the hip was diagnosed by hip joint x-ray. 
Therefore, she took NSAIDs, and received conservative therapies such as diet and muscle training. However, pain in the hip joint 
increased and her activity of daily life (ADL) decreased at the age of 50, although she continued to receive the conservative therapies. At 
the age of 52, she consulted our department requesting Japanese Oriental (Kampo) Medicine. Kampo formulae; Keishikaryojutsubuto 
(12Tab/day: Kuracie Co. Ltd. Japan), and Boiougito (7.5 g/day: Kuracie Co. Ltd. Japan), were administered. Treatment for 3 months 
resulted in a decrease in the left hip joint pain using visual analogue scale (VAS) and improvement of her ADL. One year later, her 
joint symptoms have not increased, and both the Harris hip score and the clinical evaluation criteria of osteoarthritis of the hip have 
improved. 
The course of this disease varies depending on the lifestyle of the patient, and Kampo formulations may offer safe, potent supplemental 
treatment.
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Introduction
Osteoarthritis  (OA)  of  the  hip  induces  regressive 
changes in the hip joint cartilage and subsequent abnor-
mality in the synovial membrane and articular capsule, 
leading to the impairment of joint function, and osseous 
changes also occur. The prevalence of this disease is not 
high,1 but coxalgia and surrounding pain and limitation 
of the range of motion occur, and subsequently limit 
ADL with the progression of lesions.
OA of the hip is classified into primary and second-
ary cases based on the presence or absence of causes. 
Primary OA of the hip is defined as coxarthrosis with 
normal hip joint alignment and acetabular formation.2 
In Japan, primary cases account for only 0.65%, and 
many cases are secondary.2 The cause of secondary 
OA of the hip in which lesions are localized in the hip 
joint includes congenital hip joint dislocation, acetab-
ular  dysplasia,  necrosis  of  the  femoral  head,  and 
Perthes’s disease. When acetabular dysplasia remains 
in the growth period, it may become OA of the hip.3 
When the femoral head is impaired with the treatment 
of congenital hip joint dislocation, deformation of the 
femoral head and neck occurs. These are the most fre-
quent causes of secondary OA of the hip.
The natural course of this disease is diverse and 
classified based on the severity of joint deformation 
into pre-, early, progressive, and end-stage coxarthro-
sis, but it does not necessarily progress with aging. 
The natural course is influenced by the lifestyle, and 
it has been reported that X-ray radiographic findings 
improved in some cases.4 Conservative or surgical 
treatment is selected in the natural course, and the 
timing is dependent on individual cases. In Japan, 
Kampo has been clinically applied for rheumatic dis-
eases for centuries. In this study, we applied Kampo 
for progressive to end-stage coxarthrosis in a female 
in her 50 s, and achieved improvement of the hip joint 
function and QOL. Herein, we report the case along 
with a literature review.
case Report
We encountered a 52-year-old woman with end-stage 
OA of the hip accompanied by acetabular dysplasia 
in whom the quality of life (QOL) was improved by 
Kampo treatment.
She  had  demonstrated  acetabular  dysplasia  at 
birth, and dislocation of the hip was treated with a 
plaster  cast. Although  anterior  coxarthropathy  was 
noted by a general practitioner at the age of 31, she 
was observed without treatment, due to the absence 
of joint symptoms. At the age of 42, she developed 
pain in the left hip joint, and early-stage OA of the 
hip was diagnosed. Therefore, she took non-steroidal 
anti-inflammatory drugs (NSAIDs), and received con-
servative therapies such as diet and muscle   training. 
However,  pain  in  the  hip  joint  increased  and  her 
ADL decreased at the age of 50. Nevertheless, she 
continued to receive conservative therapies, although 
her symptoms did not change. At the age of 52, she 
consulted our department requesting Japanese Orien-
tal (Kampo) Medicine. There were no abnormalities 
on blood and biochemical analysis. Hip joint X-ray 
showed end-stage OA in the left hip joint (Fig. 1). 
We administered the Kampo formulae; Keishikaryo-
jutsubuto (12Tab/day: Kracie Co. Ltd. Japan), and 
Boiougito (7.5 g/day: Kracie Co. Ltd. Japan), accord-
ing to the traditional diagnostic system5. The arthral-
gia was evaluated by visual analogue scale (VAS). 
Treatment for 3 months resulted in a decrease in hip 
joint pain as well as improvement of her ADL. One year 
later, her joint symptoms have not increased, and both 
the Harris hip score6 and the Japanese   Orthopaedic 
Association  (JOA)  hip  score7  have  improved 
(Table  1).  Although  Kampo  treatment  continued 
over one year without discontinuation, there were no 
adverse effects.
Discussion
Osteoarthritis  of  the  hip  begins  with  degeneration 
or wear of the joint cartilage, and various articular 
Figure 1. Hip joint X-ray. The image shows joint space narrowing, osteo-
sclerosis and osteophyte formation in left hip joint, accompanied by the 
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changes progress. It is considered that degeneration and 
wear of cartilage occur when mechanical loads, such as 
labor, exercise, and trauma, are added to background 
factors, such as race, gender, aging, obesity, and   heredity. 
The  metabolic  disorder  of  chondrocytes  occurs  and 
  cartilage destruction progresses, which induces inflam-
mation of the synovial membrane and causes swelling 
of the joint and bone destruction. It progresses from pre-
coxarthrosis → early stage → progressive stage → end 
stage in the general natural course, and various clinical 
symptoms appear in each disease stage.
There is ‘primary’ and ‘secondary’ osteoarthritis of the 
hip, as described above, and the presented case involved 
acetabular dysplasia-associated secondary coxarthrosis. 
In Japan, most patients with this disease are female, as 
was this patient. In treatment, conservative treatment is 
prioritized, such as instruction in daily living and physi-
cal and drug therapies, but some physicians consider 
that surgery in the early stage is desirable, even though 
symptoms  are  mild,  when  progression  is  apparently 
  predicted. Various surgical methods have been proposed 
corresponding to the condition and stage of acetabular 
dysplasia and coxarthrosis (various osteotomy proce-
dures, shelf operation, and total hip replacement).
The  patient  showed  end-stage  coxarthrosis  on 
X-ray radiography, and felt pain not only while going 
up and down stairs but also when walking, limiting 
ADL. However, pain was rapidly alleviated after the 
initiation of Kampo treatment (Keishikaryojutsubuto 
and Boiougito) and ADL improved. Methods to judge 
therapeutic  effects  on  osteoarthritis  of  the  hip  are 
roughly divided into comprehensive health scales8,9 
widely covering physical functions through mental 
health and disease-specific scales specialized for spe-
cific diseases including coxarthrosis. Of the latter, the 
Harris hip score6 is the most internationally common 
criteria. It is comprised of pain (44 points),   function 
(47  points),  deformation  (4  points),  and  range  of 
motion (5 points). Pain is divided into 6 categories, and 
function is comprised of the walking ability (33 points) 
including claudication, support for walking,   walking 
distance, and daily living activities (14 points) includ-
ing  going  up  and  down  stairs,  wearing  shoes  and 
socks, sitting, and the use of public   transportation. 
The  clinical  evaluation  criteria  of  osteoar-
thritis of the hip most commonly used in Japan are the 
hip  joint  function  assessment  criteria  established 
by  the  Japanese  Orthopedic Association  (JOA  hip 
score).7 The current JOA hip score was prepared in 
1995 based on the old JOA hip score established in 
1971, and it is comprised of the following 4 items: 
pain (40 points), range of motion (20 points), walk-
ing  ability  (20  points),  and  daily  living  activities 
(20 points). Categories proposed by Charnley, such as 
unilateral, bilateral, and multiple joint developments, 
were adopted. The maximum score of the range of 
motion is 20 points, accounting for a large proportion 
of the overall score, compared to that in the Harris hip 
score. In this patient, the JOA and Harris hip scores 
improved over the about one-year course, and so we 
consider that the objective effect of Kampo treatment 
was exhibited.
In Japan, Kampo drugs are covered by national 
health  insurance  and  clinically  applied  for  various 
diseases. Arthralgia has been treated with Kampo for 
centuries, and many Kampo formulations are admin-
istered for osteoarthritis,10 rheumatoid arthritis,11 and 
psoriatic arthritis.12 This kind of remedy is often used 
with several joints such as a knee joint13 in addition to 
hip joint caused by some pathogenesis such as degen-
eration, metabolism or inflammation. Although there 
has been no report on administrations of Boiogito and 
Keishikaryojutsubuto for osteoarthritis of the hip, an 
effect on osteoarthritis of the knee comparable to that 
of NSAIDs and synergistic effect with NSAIDs have 
been reported.14
The  mechanism  of  the  effect  of  Kampo  on 
  osteoarthritis has not been clarified. Pathologically, 
cracks  and  erosion  occur  in  the  cartilage  surface 
in  excessively  loaded  regions,  loosing  joint  carti-
lage, in osteoarthritis of the hip. In the deep layer of 
joint cartilage, blood vessels invade calcified carti-
lage, and subchondral bone comes to exhibit a bone 
effect.  On  the  other  hand,  osteophytes  are  formed 
in  non-loaded  regions.  For  rheumatoid  arthritis, 
Table 1. The change of JoA and Harris scores.
Date Mar. 17  
20xx
Apr. 17  
20xx
July. 10  
20xx
Apr. 9  
20xx+1
JoA hip score 
 r  
 L
 
86 
68
 
85 
74
 
82 
76
 
85 
88
Harris score 
 r  
 L
 
81 
60.8
 
89 
75
 
87 
77
 
97 
93
Abbreviation: JoA, The Japanese orthopaedic Association.7
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an    immunomodulatory  effect  of  Kampo  has  been 
shown,15  and  the  inhibition  of  bone  destruction  in 
some  cases  has  been  reported.16  The  inhibition  of 
bone turnover in osteoarthritis is assumed.
Additionally,  there  is  another  problem  in  this 
kind of treatment. Namely, Kampo Medicine has the 
important feature that differ from Western Medicine; 
the diagnostic system in Kampo medicine is different 
from that in Western medicine. Therefore, it is surely 
thought that Kampo diagnosis may not be easy for 
readers  to  understand. When  we  treat  RA  patients 
with  Kampo  Medicine,  it  is  necessary  to  make  a 
Kampo diagnosis as well as a diagnosis by Western 
medicine.  This  issue  makes  it  difficult  to  perform 
controlled clinical trials. In this case, we selected the 
keishikaryojutsubuto and boiogito according to the 
traditional  diagnosis  system.  The  target  group  for 
keishikaryojutsubuto  and  boiogito  is  follows:  easy 
fatigability, coldness, obesity, sweating with swollen 
joints.5,17
Furthermore, Kampo formulae are generally com-
posed of several herbal components, but not purified 
chemical compound. Therefore it is considered that 
these  remedies  are  safe.  However,  pseudoaldoster-
onism by licorice root is well known to be an adverse 
effects of herbal medicine, and there are also allergic 
effects, such as skin eruptions and liver injury, that 
can be induced by crude drugs.18–20
In summary, we reported a patient with end-stage 
osteoarthritis of the hip accompanied by acetabular 
dysplasia in whom the QOL was improved by Kampo 
treatment. Although the clinical use of this remedy 
should be with careful deliberation due to the absence 
of evidence, the course of this disease varies depend-
ing on the lifestyle among patients and Kampo formu-
lations may offer safe, potent supplemental treatment. 
The clinical course of a present patient may open the 
way to the achievement of randomized controlled tri-
als and the further basic analysis of this remedy in the 
future.
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